0.5968

3.25% 0.0157

Elevation Oncology Inc (ELEV)

Overview News Price History Financials Discussions Forecast

Elevation Oncology Inc stock is traded at $0.5968, with a volume of 285.16K. It is up +3.25% in the last 24 hours and up +2.53% over the past month. Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Previous Close:

$0.5811

Open:

$0.598

24h Volume:

285.16K

Relative Volume:

0.41

Market Cap:

$34.45M

Revenue:

Net Income/Loss:

$-41.95M

P/E Ratio:

-0.1667

EPS:

-3.58

Net Cash Flow:

$-38.34M

1W Performance:

+3.39%

1M Performance:

+2.53%

6M Performance:

-83.91%

1Y Performance:

+27.44%

1-Day Range:

$0.5713

$0.6178

1-Week Range:

$0.5221

$0.6178

52-Week Range:

$0.4401

$5.8299

Elevation Oncology Inc Stock (ELEV) Company Profile

Name

Elevation Oncology Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(716) 371-1125

Address

101 FEDERAL STREET, BOSTON

Employee

Twitter

Next Earnings Date

2024-08-05

Latest SEC Filings

ELEV's Discussions on Twitter

Compare ELEV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELEV	0.6025	34.45M	0	-41.95M	-38.34M	-3.58
VRTX	447.61	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.94	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	592.97	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.87	24.49B	3.30B	-501.07M	1.03B	11.54

Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-23-21	Initiated	H.C. Wainwright	Buy

Elevation Oncology Inc Stock (ELEV) Latest News

Nov 15, 2024

Logos Global Management LP Adjusts Stake in Elevation Oncology I - GuruFocus.com

Nov 15, 2024

OrbiMed Advisors LLC Increases Stake in Elevation Oncology Inc - GuruFocus.com

Nov 15, 2024

Nov 12, 2024

Elevation Oncology's SWOT analysis: promising ADC stock faces key data readout - Investing.com

Nov 12, 2024

Nov 06, 2024

Elevation Oncology’s Q3 2024 Highlights and Financial Report - TipRanks

Nov 06, 2024

Goldman Sachs Group Inc's Strategic Acquisition in Elevation Onc - GuruFocus.com

Nov 06, 2024

Elevation Oncology's Cancer Drug Shows 43% Response Rate, Secures FDA Fast Track | ELEV Stock News - StockTitan

Nov 06, 2024

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements - PR Newswire

Nov 06, 2024

Nov 05, 2024

Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com

Nov 05, 2024

Oct 25, 2024

Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart

Oct 25, 2024

Oct 22, 2024

AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research

Oct 22, 2024

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance

Oct 22, 2024

Oct 19, 2024

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN

Oct 19, 2024

Oct 17, 2024

GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - MSN

Oct 17, 2024

Oct 16, 2024

Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News

Oct 16, 2024

Oct 14, 2024

Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex

Oct 14, 2024

It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News

Oct 14, 2024

Oct 11, 2024